Development of negamycin, a novel class of antibiotic for Gram-negative bacterial infections

Antimicrobial resistance threatens effective prevention and treatment of microbial infections. Over two million hospitalized patients acquire infection from antimicrobial resistant microbes resulting in more than 23,000 deaths in North America. Therefore, development of a novel class of antimicrobials is in urgent need. The goal of our research project is to develop a novel antibiotic for the treatment of drug-resistant bacterial infections. This antibiotic targets ribosome to inhibit protein synthesis. We are introducing chemical modifications and analyzing antimicrobial activity in order to select a more potent analogue of this antibiotic for clinical use. The company is in developing stage and will benefit from the academic expertize and established experimental set-ups to speed up their research program.

Faculty Supervisor:

John Rohde

Student:

Hirendrasinh Parmar

Partner:

Appili Therapeutics Inc

Discipline:

Biology

Sector:

Life sciences

University:

Dalhousie University